Purpose: To explore the association between retinal vein occlusion (RVO) and incident cancer. Methods: All Danish citizens with a first-time diagnosis of RVO and no previous diagnosis of cancer in the period from 1 January 2004 to 31 December 2014 were included. Five likewise cancer-free, age-and gender-matched controls were included in a control cohort. All were followed up for 5 years or until either first diagnosis of cancer or death. Proportional hazards models with adjustment for age, gender, year of diagnosis and covariates and death as competing risk were used to estimate the risk of being diagnosed with cancer. Results: There were 7963 RVO patients without cancer at the time of diagnosis, and all could be matched to likewise cancer-free controls. Half of RVO patients were male, and the median age at RVO diagnosis was 70 years (61-79). The control cohort was similar in terms of gender and age. The risk of cancer within 1 year was 1.8 among RVO patients and 1.5 among controls. The crude risk of cancer was 1.22 (1.11;1.34) and upon full adjustment 1.15 (1.05;1.27). No time dependency was detected, and the types of cancer developed in RVO patients and controls were similar. Conclusion: Retinal vein occlusion (RVO) diagnosis is associated with an increased risk of being diagnosed with cancer. This risk is likely to reflect shared risk factors rather than a causal association.
Introduction
Retinal vein occlusion (RVO) is the most common retinal vascular disease after diabetic retinopathy. Retinal vein occlusion (RVO) can manifest as a central, hemicentral or branch RVO (Orth & Patz 1978; Green et al. 1981) . The major complications of RVO are retinal ischaemia leading to neovascularization of the iris or retina and macular oedema (Ehlers & Fekrat 2011) .
Retinal vein occlusion (RVO) is a common cause of vision loss, and its prevalence is approximately 5/1000, increasing steeply with advancing age (Yau et al. 2008; Rogers et al. 2010) . Risk factors for RVO are both systemic and local conditions within the eye (Jaulim et al. 2013) . Consistently demonstrated risk factors with high prevalence in the population are hypertension, vascular disease, diabetes and glaucoma (Stem et al. 2013) . Associations have also been found with less frequently encountered conditions such as thrombophilia, hyperviscosity syndromes, vasculitis and some forms of thrombophilia (Janssen et al. 2005; Rehak & Wiedemann 2010; Kirkegaard et al. 2017) .
Retinal vein occlusion (RVO) has shown an association with increased overall mortality, stroke and myocardial infarction (Woo et al. 2016 ), but there is little information on the effect of targeted secondary prevention in RVO.
Both the Danish and British and American AAO clinical guidelines for management of RVO recommend optimized control of systemic blood pressure and diabetes but disagree on general screening for other systemic diseases (Sivaprasad et al. 2015; Pulido et al. 2016) .
Cancer is associated with a severalfold increase in the incidence of venous thromboembolism (VTE) and, apart from the known excess risk associated with chemotherapy (Falanga et al. 2015; Ratib et al. 2016) , apparently unprovoked VTEs often precede de novo diagnoses of malignancy (Baron et al. 1998; Falanga et al. 2015) . Thrombi are found in veins distant from the site of cancer as the cancerinduced systemic coagulopathy is at least partly mediated by a systemic prothrombotic shift mediated by malignant cells (Falanga et al. 2015) . Case reports of RVO as the initial symptom of haematological malignancies (Chiang et al. 2000; Borgman 2016 ) and also solid cancers with no anatomical relation to the eye (Asensio-S anchez et al. 2013) are abundant, but larger clinical studies are lacking. Hypercoagulability and hypofibrinolysis have been demonstrated in RVO (Cellai et al. 2012) , as would be expected if coagulopathy induced by occult cancer was involved, but a history of cancer was not significantly associated with incident RVO (Bertelsen et al. 2014 ). The direct association between cancer and RVO has not been examined. We hypothesized that cancers, due to their diagnostic lag time, may increase the risk of RVO and that the occurrence of RVO therefore may indicate an increased risk of being diagnosed with cancer. In this matched cohort study, we examine whether the probability of having a de novo diagnosis of cancer is related to previous occurrence of RVO.
Materials and methods
The RVO cohort All contacts to both public and private hospitals in Denmark in the period from 1994 to 2015 were identified in the Danish National Patient Registry. This registry covers the whole country with 5.5 million inhabitants (Lynge et al. 2011) . Contacts for RVO in the period from 1 January 2004 to 31 December 2014 were identified as were all contacts for cancer (excluding nonmelanoma skin cancer), atrial fibrillation/flutter, venous thromboembolism, thrombophilia, vascular disease and systemic connective tissue disease (see Table S1 ). Cancer types were defined by the main organ system involved. From the National Register of Medicinal Product Statistics, redeemed prescriptions for antidiabetics and antihypertensives were retrieved. Information on gender, date of birth and date of death was retrieved from the Danish Civil Registration System. Patients were included in the RVO cohort at the date of their first RVO diagnosis (the index date) provided they had no recorded contacts for malignant disease before or at that date and were 18 years or over. The reason for only including incident cancers was to avoid measuring any excess risk that might be attributable to treatment, for example antineoplastic drugs (Falanga et al. 2015; Ratib et al. 2016 ).
The matched cohort
Every RVO patient was risk set matched to 5 controls in the Danish population at the index date. Citizens were eligible for sampling in periods where they were 18 years or over, had no previous contacts for cancer and were alive. Matching criteria were gender and year of birth.
Follow-up
Both RVO and control subjects were followed up for 5 years and to the event of either first contact for cancer, death of any cause, or the date of 31 December 2015, whichever happened first.
Statistics
All analyses were performed using SAS 9.4 and R version 4.3.1 (packages prodlim, survival and timereg) Chisquared tests were used for comparison of distributions of cancer types. Median follow-up time was estimated from a reverse Kaplan-Meier model. Association between an RVO diagnosis (main exposure) and time to either first cancer contact (main outcome) or death (competing outcome) was modelled using the cause-specific Cox proportional hazards technique with clustering of a case and the matched controls. The model structure was decided upon before analyses were conducted.
The proportionality assumption was visually evaluated using Sch€ oenfeld residuals and time dependency was formally tested for by inclusion of a time-dependent coefficient in the main model. Adjusted models furthermore included categories of age at index, gender, calendar year and comorbidities at index. The level of significance was 0.05.
Sensitivity analysis
In sensitivity analyses, time to nonhaematological cancer or death and haematological cancer or death was modelled.
Ethics
Retrospective registry-based studies do not require approval from the Research Ethics Committee System. The Danish Data Protection Agency had approved the use of data for this study (Ref. No: 2008-58-0028) .
Results
There were 9025 first-time diagnoses of RVO recorded for patients older than 18 years of age in the period from 1 January 2004 and 31 December 2014, corresponding to an incidence of 1.5/ 10 000 person-years. Of the patients with first-time RVO diagnoses, 7963 had not had cancer recorded before the diagnosis of RVO and were included in the study. The median age at diagnosis was 70 years and the proportions of men and women were equal (Table 1) .
Matching on sex and year of birth was successful for all RVO patients and the control cohort therefore included 39 815 individuals with the same age and gender distributions as the RVO cohort. The median follow-up time was 5 (IQR 3.3-5) years. At baseline, comorbidities were more frequently present in the RVO cohort. The distributions of cancer types being diagnosed in RVO patients and controls, respectively, were similar (chisquare test, p = 0.67) ( Table 2) . Rates of cancer and death within 1 and 3 years, respectively, were higher in the RVO cohort than among controls (Table 3 ). The cumulative incidences of being diagnosed with cancer or death, respectively were likewise higher in the RVO cohort and increased in an approximately linear fashion implying stable rates over time from the RVO diagnosis (Fig. 1) . In a crude analysis, a diagnosis of RVO was associated with a 22% increased risk of being diagnosed with cancer (Table 4) 
Discussion
This study demonstrates an increased incidence of cancer in patients with retinal vein occlusion compared to ageand gender-matched controls. The types of cancer detected in patients with RVO are not different from the types found in controls and the excess risk seems to be of stable magnitude over time from RVO diagnosis.
The strengths of our study are the considerable number of patients included, the complete coverage of all Danish citizens, the high reliability of the Danish medical registers and the unbiased sampling of age-and gendermatched controls from the general population. Also, our examining only incident cancer in a previously cancerfree population is a strength as it allows us to assess the association between RVO and cancer without any superimposed effect from cancer treatment.
The most important limitation to our study is low statistical power despite our extracting diagnoses from a population of more than five million over 11 years. The validity of an RVO diagnosis in the Danish National Patient Registry is unknown, but the positive predictive value is likely to be high, as only ophthalmologist makes this diagnosis. Another important limitation is the pooling of central and branch RVO, which cannot be distinguished in the register. As the underlying pathologies are known to be somewhat different (Kolar 2014) , this pooling might have biased our results.
Theoretically, the increased risk of cancer in patients diagnosed with RVO could be either a direct causal association or a reflection of a distinct set of risk factors in the RVO cohort compared to the controls. Our study lends support to the association mainly being caused by shared risk factors. Firstly, we did not find a peak in cancer incidence immediately after the diagnosis in the RVO patients, which would be expected if cancer was the causal agent and as was seen in a study of cancer incidence following systemic VTE (Sørensen et al. 1998 ). Secondly, we did not find that haematological cancers made up a larger fraction of the total number of cancers in the RVO group, which would likely have been the case if the RVO was provoked by a systemic coagulopathy or a hyperviscosity syndrome as these conditions are seen more commonly in cases of haematological malignancy. Finally, an attenuation of the association between RVO and cancer was seen upon adjustment for other systemic diseases as would be the result if this adjustment partly adjusted for the presence of underlying risk factors such as smoking or metabolic syndrome.
Our study was not designed to assess the benefit of screening patients with RVO for underlying systemic disease, which would have required a completely different study design. Prevalent systemic diseases such as hypertension and diabetes are seen more frequently in the RVO population compared to the controls, but as this reflects the treatment that has already been instigated at the time of diagnosis of RVO, the benefit of intensified screening cannot be inferred. The same reservation does not apply to screening for cancer, but the absolute risk differences are so moderate that screening is unlikely to be a rational approach. This is the largest study investigating the association between cancer and RVO. We found an excess risk of cancer in RVO, but the risk is likely to reflect shared risk factors rather than a causal association. Future studies should evaluate the benefit of risk factor identification and modification in patients with RVO.
